NO20072136L - Substance that promotes GH secretion and its use - Google Patents
Substance that promotes GH secretion and its useInfo
- Publication number
- NO20072136L NO20072136L NO20072136A NO20072136A NO20072136L NO 20072136 L NO20072136 L NO 20072136L NO 20072136 A NO20072136 A NO 20072136A NO 20072136 A NO20072136 A NO 20072136A NO 20072136 L NO20072136 L NO 20072136L
- Authority
- NO
- Norway
- Prior art keywords
- individual
- improve
- secretion
- improving
- promotes
- Prior art date
Links
- 230000028327 secretion Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 206010007733 Catabolic state Diseases 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
Abstract
Oppfinnelsen angår anvendelsen av en GH-sekresjonsfremmer (for eksempel GRF eller en analog derav) for (1) å endre et lipid parameter i et individ; (2) å endre en kroppssammensetningsparameter i et individ; (3) å behandle en tilstand karakterisert ved manglende eller nedsatt bendannelse i et individ; (4) å forbedre dagtids årvåkenhet og/eller kognitiv funksjon i et individ; (5) å forbedre en metabolsk tilstand i et individ; (6) å forbedre anabolisme i en katabolsk tilstand i et individ, og/eller (7) å forbedre og/eller rekondisjonere immun funksjon i et individ.This invention relates to the use of a GH secretion promoter (e.g., GRF or an analog thereof) to (1) alter a lipid parameter in an individual; (2) changing a body composition parameter in an individual; (3) treating a condition characterized by missing or impaired bone formation in an individual; (4) improving daytime alertness and / or cognitive function in an individual; (5) improving a metabolic state in an individual; (6) to improve anabolism in a catabolic state in an individual, and / or (7) to improve and / or recondition immune function in an individual.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2485472A CA2485472C (en) | 2004-10-20 | 2004-10-20 | Gh secretagogues and uses thereof |
US10/969,463 US7316997B2 (en) | 2003-05-29 | 2004-10-20 | GH secretagogues and uses thereof |
PCT/CA2005/001611 WO2006042408A1 (en) | 2004-10-20 | 2005-10-20 | Gh secretagogues and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072136L true NO20072136L (en) | 2007-07-16 |
Family
ID=36202645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072136A NO20072136L (en) | 2004-10-20 | 2007-04-24 | Substance that promotes GH secretion and its use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1812048A4 (en) |
JP (1) | JP2008516994A (en) |
KR (1) | KR101228229B1 (en) |
AU (1) | AU2005297366B2 (en) |
NO (1) | NO20072136L (en) |
WO (1) | WO2006042408A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160061439A (en) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Stitched polypeptides |
RU2009140731A (en) * | 2007-04-04 | 2011-05-10 | Тератекнолоджиз Инк. (Ca) | PHARMACEUTICAL COMPOSITIONS CONTAINING GHRH MOLECULES |
KR102104762B1 (en) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
US8361964B2 (en) | 2011-04-21 | 2013-01-29 | Theratechnologies Inc. | Growth hormone releasing factor (GRF) analogs and uses thereof |
KR20140100937A (en) | 2011-10-18 | 2014-08-18 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
CN107216380A (en) | 2012-02-15 | 2017-09-29 | 爱勒让治疗公司 | Peptidomimetic macrocyclic compound |
CN104144695A (en) | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
KR20150082307A (en) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | Disubstituted amino acids and methods of preparation and use thereof |
BR112017005598A2 (en) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | peptidomimetic macrocycles and their uses |
EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458764B1 (en) * | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
US6696063B1 (en) * | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
EP2382984A3 (en) * | 2003-05-29 | 2011-11-23 | Theratechnologies Inc. | GRF analog compositions and their use |
CA2542433A1 (en) * | 2003-10-20 | 2005-04-28 | Theratechnologies Inc. | Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
-
2005
- 2005-10-20 KR KR1020077011178A patent/KR101228229B1/en active IP Right Grant
- 2005-10-20 AU AU2005297366A patent/AU2005297366B2/en active Active
- 2005-10-20 EP EP05797145A patent/EP1812048A4/en not_active Withdrawn
- 2005-10-20 JP JP2007537087A patent/JP2008516994A/en active Pending
- 2005-10-20 WO PCT/CA2005/001611 patent/WO2006042408A1/en active Application Filing
-
2007
- 2007-04-24 NO NO20072136A patent/NO20072136L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR101228229B1 (en) | 2013-01-31 |
KR20070069207A (en) | 2007-07-02 |
AU2005297366A1 (en) | 2006-04-27 |
AU2005297366A2 (en) | 2006-04-27 |
JP2008516994A (en) | 2008-05-22 |
WO2006042408A9 (en) | 2007-05-24 |
EP1812048A1 (en) | 2007-08-01 |
EP1812048A4 (en) | 2012-01-18 |
AU2005297366B2 (en) | 2011-12-08 |
WO2006042408A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072136L (en) | Substance that promotes GH secretion and its use | |
EA201000399A1 (en) | COMPOSITIONS AND METHODS OF USING PRO-ISLAND PEPTIDES AND THEIR ANALOGUES | |
ATE463247T1 (en) | BUPROPION METABOLITES FOR THE TREATMENT OF ANXIETY | |
WO2003104273A3 (en) | Therapeutic epitopes and uses thereof | |
ATE450269T1 (en) | PEPTIDE PYYÄ3-36Ü FOR THE TREATMENT OF METABOLIC DISEASES | |
YU37304A (en) | Specific binding agents of human angiopoietin-2 | |
MXPA03010843A (en) | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease. | |
EA200600055A1 (en) | AGONISTS OF MELANOCORTIN 4 (MK4) RECEPTOR AND THEIR APPLICATION | |
MXPA05007182A (en) | Complexes of protein crystals and ionic polymers. | |
HK1077518A1 (en) | Peptides that modulate nerve growth factor (ngf) activity, their compositions and use | |
HK1091112A1 (en) | Compounds and methods for increasing neurogenesis | |
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
GB0108592D0 (en) | Therapeutic agents | |
DE60110054D1 (en) | Cardioprotektive phosphonate | |
MA29222B1 (en) | COSMETIC COMPOSITION WITH APPROPRIATE SKIN APPLICATION FOR RELAXING EXPRESSION WRINKLES | |
HK1080467A1 (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
EA200500782A1 (en) | TREATMENT OF HEMORRHAGIC SHOCK | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
HK1110768A1 (en) | 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | |
RS8504A (en) | Novel cyclohexil sulphones | |
SG162829A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
WO2003066022A3 (en) | Stable pharmaceutical composition useful for treating gastrointestinal disorders | |
DE60228988D1 (en) | MONOHYROXYCARBAMEZEPINE FOR USE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF AFFECTIVE PSYCHOSIS, ATTRACTIVE DISORDERS AND NEUROPATHIC PAIN | |
WO2003094851A3 (en) | 1,1- and 1,2-bisphosphonates as apoliprotein e modulators | |
EP2275118A3 (en) | Pancreas-specific proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |